BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AllRock Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies AllRock Bio's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07175038-545@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ROC-101: Phase 2 readout est. (NCT07175038)
DESCRIPTION:ROC-101\, phase 2\, Pulmonary Arterial Hypertension.\nStudy: A 
 Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) an
 d Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH
 ) (ROCSTAR STUDY)\nEstimated primary completion: March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/roc-101#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07175038
URL:https://assetmemo.bio/drug/roc-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
